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INTRODUCTION
The efficacy of myelosuppressive chemotherapy regimens is 
often restricted by dose-limiting toxicities that can delay sub-
sequent treatment cycles. Febrile neutropenia (FN) is a com-
mon adverse effect of chemotherapy, sometimes causing life-
threatening complications [1]. Chemotherapy-induced FN 
may also result in modifications to the chemotherapy dose or 
schedule, which may compromise treatment efficacy [2]. In 
breast cancer, there is evidence supporting a close correlation 
between maintaining the relative dose intensity (RDI) of neo-
adjuvant or adjuvant chemotherapy and the clinical outcomes 
of patients [3,4]. Prevention of chemotherapy-induced FN is 
therefore a medical priority in neoadjuvant or adjuvant set-
tings.
Recombinant granulocyte-colony stimulating factor (G-
CSF) products have emerged as effective therapies for reduc-
ing the duration and incidence of chemotherapy-induced 
neutropenia and FN by stimulating neutrophil proliferation 
and differentiation in cancer patients [5]. Clinical guidelines 
from the American Society of Clinical Oncology (ASCO) and 
the National Comprehensive Cancer Network (NCCN) in the 
United States, and from the European Organization for Re-
search and Treatment of Cancer (EORTC), all recommend 
that G-CSF should be administered prophylactically if the risk 
of FN is greater than 20%. In the case of chemotherapeutic 
regimens with an intermediate risk of FN (10%–20%), the 
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Purpose: Doxorubicin/cyclophosphamide followed by docetaxel
chemotherapy (AC-D) is an intermediate risk factor (incidence of
10%–20%) for febrile neutropenia (FN) in breast cancer. How-
ever, the reported incidence of FN while using this regimen was 
obtained mostly from Western breast cancer patients, with little 
data available from Asian patients. This study aimed to assess 
the incidence of FN in Korean breast cancer patients and to de-
scribe clinical variables related to FN. Methods: From September
2010 to February 2013, data from the Yonsei Cancer Center reg-
istry of breast cancer patients who received neoadjuvant or ad-
juvant chemotherapy with four cycles of AC-D (60 mg/m2 doxo-
rubicin, 600 mg/m2 cyclophosphamide every 3 weeks for four 
cycles followed by 75 mg/m2 or 100 mg/m2 docetaxel every 3 
weeks for four cycles) were analyzed. The incidence of FN, FN 
associated complications, dose reduction/delays, and relative 
dose intensity (RDI) were investigated. Results: Among the 254 
patients reported to the registry, the FN incidence after AC-D 
chemotherapy was 29.5% (75/254), consisting of 25.2% (64/254) 
events during AC and 4.7% (12/254) during docetaxel chemo-
therapy. Dose reductions, delays, and RDI less than 85.0% dur-
ing AC were observed in 16.5% (42/254), 19.5% (47/254), and 
11.0% (28/254) of patients, respectively. Patients with FN events 
frequently experienced dose reduction/delays, which eventually 
led to a decreased RDI. Conclusion: The incidence of FN during 
AC-D neoadjuvant or adjuvant chemotherapy was higher than 
expected in Korean breast cancer patients. Whether these pa-
tients should be classified as a high-risk group for FN warrants 
future prospective studies.
Key Words: Breast neoplasms, Chemotherapy-induced febrile neutropenia, 
Cyclophosphamide, Docetaxel, Doxorubicin
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guidelines emphasize the importance of considering several 
risk factors for evaluating a patient’s overall risk for FN [6,7]. 
These risk factors include old age, previous chemotherapy or 
radiotherapy, pre-existing neutropenia or infection, poor per-
formance status, and poor renal or hepatic functions. How-
ever, ethnic or geographic differences in response to the same 
chemotherapy regimen have so far been poorly investigated.
Sequential doxorubicin/cyclophosphamide and docetaxel 
(AC-D) is a widely used neoadjuvant and adjuvant chemo-
therapy regimen for breast cancer. The incidence of FN ranges 
widely from 3.1% to 25%, and many guidelines including the 
NCCN, ASCO, and EORTC have categorized this regimen 
into the intermediate risk group (e.g., the risk of FN is 10%–
20%) [8,9]. However, most of these studies were conducted in 
Western countries [10,11], and there have been few reports on 
the incidence of FN in Asian countries.
Several studies showed that the incidence of hematologic 
toxicity caused by chemotherapy differs between ethnic 
groups [12-15]. Here we report the incidence of FN with AC-D 
as neoadjuvant or adjuvant chemotherapy in Korean breast 
cancer patients.
METHODS
This study was approved by the Institutional Review Board 
of Yonsei Cancer Center (approval number: 4-2015-1154). 
Breast cancer patients who received neoadjuvant or adjuvant 
sequential AC-D from September 2010 to February 2013 were 
analyzed from the Yonsei Cancer Center registry of breast 
cancer. Patients with previous exposure to chemotherapeutic 
agents; inflammatory breast cancer; major cardiovascular, liv-
er, or renal diseases; active infection; inadequate follow-up; or 
preexisting neutropenia were excluded in order to minimize 
other confounding factors (Figure 1).
Four cycles of doxorubicin (60 mg/m2) and cyclophospha-
mide (600 mg/m2) followed by four cycles of docetaxel (75 
mg/m2 or 100 mg/m2) were administered. Blood samples were 
collected before each cycle for complete blood cell counts with 
differential and serum samples for chemistry assays. During 
the first cycle, nadir blood cell counts were measured between 
days 10 and 14. After the first cycle, nadir blood cell counts 
were measured selectively (Figure 2).
Data on patient demographics, pretreatment laboratory pa-
956 Early breast cancer with surgery
288 Neoadjuvant/adjuvant AC-D
254 Patients included for analysis
138 Neoadjuvant chemotherapy 116 Adjuvant chemotherapy
34 Ineligible 
   3 Previous exposure to chemotherapy 
   3 Inflammatory breast cancer 
   14 Major comorbidities 
      8 Cardiovascular disease 
      4 Liver dysfunction 
      2 Renal dysfunction
   3 Active infection 
      2 Pulmonary tuberculosis 
      1 Chronic sinusitis 
   9 Inadequate follow-up 
      7 Transfer to other hospitals 
      2 Attempted suicide/die owing to suicide 
   2 Other reasons 
      1 Man 
      1 Pre-existing neutropenia 
Figure 1. The consort diagram shows the patient inclusion and exclusion criteria.
AC=doxorubicin/cyclophosphamide; D=docetaxel.
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rameters, and tumor characteristics were collected. Patients 
were divided into four subtypes in accordance with the St. 
Gallen 2011 consensus [16]. The incidence of FN, FN-related 
hospitalization requiring intravenous antibiotics, FN associat-
ed with shock or death, subsequent dose reduction/delay, and 
other hematologic toxicities according to the common termi-
nology criteria for adverse events (CTCAE), version 4.02, 
were investigated. FN was defined as neutropenia (< 500 neu-
trophils/µL or < 1,000 neutrophils/µL for over 48 hours) with 
a febrile event (oral temperature ≥ 38.3°C, or ≥ 38.0°C for 
over 1 hour) observed by medical staff. Dose reduction was 
defined as reductions in the delivered dosages of agents ad-
ministered relative to the standard values, and dose delay was 
defined as a chemotherapy interval of more than 28 days 
(more than 7 days delay) or early cessation of chemotherapy. 
RDI was calculated by the method described in Supplementa-
ry Table 1 (available online) [17].
All patients received neither G-CSF nor antibiotics as pri-
mary prophylaxis for FN. Secondary prophylaxis with G-CSF, 
antibiotics for FN, and dose reduction/delay were adminis-
tered at the physicians’ discretion. Filgrastim was the most 
commonly used G-CSF analogue, and choice of antibiotics 
was based on NCCN guidelines.
Statistical analyses were performed using SPSS version 21.0 
for Window (IBM Corp., Armonk, USA). Descriptive statis-
tics were used for baseline characteristics. Binomial two-sided 
95% confidence intervals (CIs) for the incidence of FN and 
dose reduction/delays were calculated. The chi-square test was 
used for comparison between categorical variables, and the 
two-sample t-test was used for comparison between continu-
ous variables. Two-sided p-values less than 0.05 were consid-
ered statistically significant.
RESULTS
Between September 2010 and February 2013, 254 Korean 
breast cancer patients receiving AC-D were recruited for the 
analysis (Table 1). The median patient age was 50 years (range, 
27–70 years) and 5.9% (15/254) of patients were more than 65 
years old. The mean body weight, body mass index, and body 
surface area were 59.3± 8.5 kg, 23.7± 3.4 kg/m2, and 1.61±  
0.11 m2, respectively. The number of patients with Eastern 
Cooperative Oncology Group performance status 1 or 2 was 
31.5% (80/254). There were 13.4% (34/254) cases of basal-like 
subtype tumors and 11.4% (29/254) cases of human epider-
mal growth factor receptor 2 (HER2) enriched subtype tu-
Figure 2. The treatment schema shows the regimen schedule.
IVH= intravenous bolus; IVF= intravenous infusion; CBC=complete 
blood cell count; SMA=serum metabolic analysis.
Doxorubichin
60 mg/m2, IVH
Cyclophosphamide
600 mg/m2, IVH
Docetaxel
75-100 mg/m2, IVF
CBC, SMA before
each cycle
Nadir CBC
Nadir CBC (optional)
3 wk
24 wk
Table 1. Baseline characteristics
Characteristic
Total (n=254) 
No. (%)
Age (yr)* 50 (27–70)
Body weight (kg)† 59.3±8.5
BMI (kg/m2)† 23.7±3.4
BSA (m2)† 1.61±0.11
ECOG
   0 174 (68.5)
   1 or 2 80 (31.5)
Stage
   IA 17 (6.7)
   IB 11 (4.3)
   IIA 78 (30.7)
   IIB 70 (27.6)
   IIIA 63 (24.8)
   IIIB 2 (0.8)
   IIIC 13 (5.1)
ER status
   Positive 191 (75.2)
   Negative 63 (24.8)
PR status
   Positive 117 (46.1)
   Negative 137 (53.9)
HER2 status
   Positive  67 (26.4)
   Negative 187 (73.6)
Subtype
   Luminal A-like 120 (47.2)
   Luminal B-like 71 (28.0)
   Basal-like 34 (13.4)
   HER2-enriched 29 (11.4)
Histology
   Ductal 237 (93.3)
   Lobular  5 (2.0)
   Mixed 12 (4.7)
BMI=body mass index; BSA=body surface area; ECOG=Eastern Coopera-
tive Oncology Group; ER=estrogen receptor; PR=progesterone receptor; 
HER2=human epidermal growth factor receptor 2.
*Expressed as median (range); †Expressed as mean±SD.
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mors. A total of 138 patients received neoadjuvant chemo-
therapy and 116 patients received adjuvant chemotherapy.
During the AC and D stages of chemotherapy 25.2% 
(64/254) and 4.7% (12/254) patients experienced FN, respec-
tively (Table 2). Overall, 29.5% of patients experienced FN 
during chemotherapy (95% CI, 23.9%–35.2%, 75/254). Dose 
reduction, delays, and RDI less than 85.0% during AC were 
observed in 16.5% (42/254), 19.5% (47/254), and 11.0% 
(28/254) of patients, respectively.
The total number of FN events during chemotherapy was 
95, including 83 events (87.4%) during AC and 12 events 
(12.6%) during D (Table 3). Of the 64 patients who experi-
enced FN during AC, 41 patients (64.1%) experienced FN in 
the first cycle. Of 95 events of FN, 66 events (69.5%) were ac-
companied by administration of intravenous antibiotics and 
five (5.3%) were accompanied by septic shock. No chemo-
therapy-related death was observed. The median duration of 
admission was 5 days, ranging from 2 to 20 days. β-Lactam/
β-lactamase inhibitors were the most frequently used intrave-
nous antibiotics (69.7%) and glycopeptides were used in six 
events (9.1%). Secondary G-CSF prophylaxis for the next cy-
cle was administered in 58 cases (61.1%). Dose reduction and 
dose delays were performed in 26.3% and 15.8% of patients, 
respectively. Fifteen patients experienced more than two 
events of FN, even with prophylactic G CSF administration, 
and dose reduction/delays were performed for these patients.
Baseline and treatment characteristics were compared be-
tween patients who experienced FN during AC and patients 
who did not (Table 4). Dose reduction and delay during AC 
chemotherapy were more frequently observed in patients who 
experienced FN (39.1% vs. 8.9%, p< 0.001; 35.9% vs. 12.6%, 
p< 0.001, respectively). The dose interval during AC was lon-
ger in patients who experienced FN (22.3 vs. 21.6 days, 
p= 0.002) and the RDI during AC was lower in patients who 
experienced FN (90.5% vs. 96.7%, p< 0.001). Patients who ex-
perienced FN during AC were more likely to have an RDI less 
than 85.0% (25.0% vs. 6.3%, p< 0.001).
We investigated other hematologic toxicities by using the 
CTCAE grading system (Supplementary Table 2, available 
online). Patients with FN during AC cycles were more likely 
to experience grade 3/4 lymphopenia, anemia, and thrombo-
cytopenia (Supplementary Table 3, available online).
DISCUSSION
This study showed that the incidence of FN during AC-D 
chemotherapy was 29.5% in breast cancer patients in Korea. 
FN events occurred frequently during AC chemotherapy 
(25.2%) and more than half of the FN events (64.1%) oc-
curred in the first cycle. Patients who experienced FN were 
more likely to have poor performance status and low pretreat-
ment albumin levels, similar to the results of a previous study 
Table 2. Incidence of febrile neutropenia, dose reduction, dose delay, 
and relative dose intensity <85.0% during doxorubicin/cyclophospha-
mide
Variable
No. of patients 
experienced
Incidence (%) 95% CI
FN during AC+D 75 29.5 23.9–35.2
FN during AC 64 25.2 19.8–30.6
FN during D 12 4.7 2.1–7.4
Dose reduction during AC 42 16.5 11.9–21.1
Dose delay during AC 47 19.5  13.7–23.3
RDI <85.0% during AC 28 11.0   7.1–14.9
CI=confidence interval; FN=febrile neutropenia; AC=doxorubicin/cyclophos-
phamide; D=docetaxel; RDI= relative dose intensity.
Table 3. Description of febrile neutropenia* (total no. of events=95, to-
tal no. of patients=75)
Variable
Observed events or patients 
No. (%)
FN during AC 83/95 (87.4)
FN during D 12/95 (12.6)
Patients experienced FN during AC 64/75 
   1st cycle 41/64 (64.1)
   2nd cycle 7/64 (10.9)
   3rd cycle 9/64 (14.1)
   4th cycle 7/64 (10.9)
Patients experienced FN during D 12/75
   5th cycle 5/12 (41.7)
   6th cycle 4/12 (33.3)
   7th cycle 3/12 (25.0)
   8th cycle 0/12 (0.0)
FN associated complications
   Admission for intravenous antibiotics 66/95 (69.5)
   Shock 5/95 (5.3)
   Death 0/95 (0.0)
Intravenous antibiotics
   β-Lactam/β-lactamase inhibitor 46/66 (69.7)
   Cephalosporin 20/66 (30.3)
   Fluoroquinolone 3/66 (4.5)
   Glycopeptide 6/66 (9.1)
Oral antibiotics
   β-Lactam/β-lactamase inhibitor 16/29 (55.2)
   Cephalosporin  9/29 (31.0)
   Fluoroquinolone 20/29 (69.0)
Secondary G-CSF prophylaxis 58/95 (61.1)
Dose reduction 25/95 (26.3)
Dose delay 15/95 (15.8)
Patients experienced FN more than twice 15/75 (20.0)
FN=febrile neutropenia; AC=doxorubicin/cyclophosphamide; D=docetaxel; 
G-CSF=granulocyte colony stimulating factor.
*Expressed as “actual number of events or patients/total number of events or 
patients” in proper circumstances.
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[18]. Patients with FN events frequently experienced dose re-
duction/delays, which eventually led to a decreased RDI. Fur-
thermore, we observed frequent hospitalization and use of in-
travenous antibiotics for the management of FN.
Previous studies reported a diverse range of FN incidence 
during AC or AC-D chemotherapy. The ECOG 1199 and 
CALBG 40101 trials reported an incidence of FN of 6.5% and 
6.0%, respectively, during adjuvant AC chemotherapy [19,20]. 
The CALGB 9741 and BCIRG-005 trials reported an inci-
dence of 6.0% and 7.7%, respectively, during adjuvant AC-D 
chemotherapy [11,21]. The GEPARDUO study documented 
an incidence of 3.7% during neoadjuvant AC-D chemother-
apy [8]. In contrast to early breast cancer patients, the FN in-
cidence was higher in patients with metastatic breast cancer 
during AC-D chemotherapy, up to 25% of those without pro-
phylactic G-CSF support [22]. Chan et al. [23] investigated 
the incidence of FN following AC chemotherapy in Asian 
countries. After the first cycle, 9.1% (17/189) of patients devel-
oped FN and after all cycles this rose to 13.8%. The authors 
pointed out that the relatively lower incidence of FN in previ-
ous randomized control trials could be attributed to patient 
selection before inclusion into the trial.
Ethnic differences in hematologic toxicity from chemother-
apeutic agents or monoclonal antibodies have been described 
in lung cancer [12,13,24] and renal cell carcinoma patients 
[14]. In breast cancer, the pharmacokinetics and pharmaco-
dynamics of doxorubicin and docetaxel are different in terms 
of nadir white blood cell count and neutrophil count between 
ethnicities [25]. Genetic polymorphisms also influence nadir 
white blood cell and neutrophil counts in patients receiving 
cyclophosphamide-based combination chemotherapy [26]. In 
these previous studies, severe hematologic toxicities were 
more frequently observed in Asian patients than in Western 
patients. These findings provide indirect evidence that Asian 
patients are more likely to experience FN during chemother-
apy. Consistent with the findings above, although the patients 
in our study did not have any of the baseline characteristics 
that elevate the risk of FN, including other comorbidities, they 
had FN events more frequently and lower RDIs during AC-D 
chemotherapy compared to study populations in previous 
studies that were mostly conducted in Western countries.
Our study has several limitations, including its relatively 
small sample size, being conducted in a single institution, and 
its retrospective nature. Indications for admission, selection of 
antibiotics, secondary G CSF prophylaxis, and dose reduc-
tion/delay were according to the individual physicians’ judg-
ment rather than protocol-defined management. Additionally, 
only FN reported officially was counted, and patients’ or care-
givers’ self-documentation of febrile events were excluded, 
Table 4. Comparison of patient and treatment characteristics by experi-
ence of febrile neutropenia during doxorubicin/cyclophosphamide (ex-
perience of febrile neutropenia versus no experience of febrile neutrope-
nia during doxorubicin/cyclophosphamide)
Characteristic
FN during 
AC (n=64) 
No. (%)
No FN during 
AC (n=190) 
No. (%)
p-value*
Age (yr)† 52 (31–68) 50 (27–70) 0.081
Body weight (kg)‡ 60.0±9.9 59.0±8.0 0.431
BMI (kg/m2)‡ 24.3±3.6 23.6±3.3 0.162
BSA (m2)‡  1.61±0.12  1.60±0.11 0.704
ECOG 0.002
   0 34 (53.1) 140 (73.7)
   1 or 2 30 (46.9)  50 (26.3)
Baseline CBC‡
   WBC (cells/µL)  5,911±1,546 6,230±1,793 0.204
   ANC (cells/µL)  3,534±1,237 3,820±1,548 0.181
   Lymphocyte (cells/µL) 1,740±663 1,794±612 0.552
   Hgb (g/dL) 12.5±1.4 12.7±1.2 0.460
   PLT (103 cells/µL) 255±78 279±73 0.025
   Baseline albumin (mg/dL)  4.16±0.42  4.28±0.34 0.016
Stage 0.809
   IA 3 (4.7)  14 (7.4)
   IB 2 (3.1)   9 (4.7)
   IIA 22 (34.4)  56 (29.5)
   IIB 20 (31.2)  50 (26.3)
   IIIA 15 (23.4)  48 (25.3)
   IIIB 0   2 (1.1)
   IIIC 2 (3.1)  11 (5.8)
ER status 0.477
   Positive 46 (71.9) 145 (76.3)
   Negative 18 (28.1)  45 (23.7)
PR status 0.313
   Positive 26 (40.6)  91 (47.9)
   Negative 38 (59.4)  99 (52.1)
HER2 status 0.306
   Positive 20 (31.2)  47 (24.7)
   Negative 44 (68.8) 143 (75.3)
Subtype 0.878
   Luminal A-like 30 (46.9) 90 (47.4)
   Luminal B-like 16 (25.0) 55 (28.9)
   Basal-like 10 (15.6) 24 (12.6)
   HER2-enriched 8 (12.5) 21 (11.1)
Histology 0.743
   Ductal 59 (92.2) 178 (93.7)
   Mixed 3 (4.7)  9 (4.7)
   Lobular 2 (3.1)  3 (1.6)
Dose reduction during AC 25 (39.1) 17 (8.9) <0.001
Dose delay during AC 23 (35.9)  24 (12.6) <0.001
Dose interval during AC (day)‡ 22.3±1.8 21.6±1.4 0.002
RDI during AC (%)‡ 90.5±10.8 96.7±6.4 <0.001
RDI <85.0% during AC 16 (25.0)  12 (6.3) <0.001
FN=febrile neutropenia; AC=doxorubicin/cyclophosphamide; BMI=body 
mass index; BSA=body surface area; ECOG=Eastern Cooperative Oncology 
Group; CBC=complete blood cell count; WBC=white blood cell count; 
ANC =absolute neutrophil count; Hgb =hemoglobin; PLT =platelet; ER = 
estrogen receptor; PR=progesterone receptor; HER2=human epidermal 
growth factor receptor 2; RDI= relative dose intensity.
*Comparison between patients who experienced febrile neutropenia and 
those who did not; †Expressed as median (range); ‡Expressed as mean±SD.
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which could imply under-estimation of the incidence of FN. 
When we included possible cases of FN in the analysis, 32.7% 
(95% CI, 26.9%–38.5%) and 28.3% (95% CI, 22.8%–33.9%) 
patients experienced FN during any cycle and during AC cy-
cles, respectively.
In conclusion, the incidence of FN during AC-D in breast 
cancer patients was 29.5%, 25.2% during AC and 4.7% during 
D chemotherapy. Patients who experienced FN had more oc-
currences of hospitalization and dose reduction/delays, which 
may compromise treatment efficacy and quality of life. Fur-
ther large prospective studies are required to define the exact 
incidence of FN in Asian patients with this regimen. In add-
ition, whether to consider the use of prophylactic G-CSF in 
Korean breast cancer patients treated with this regimen needs 
to be validated in future prospective clinical trials.
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